Elisha M Wachman1, Alice Wang1, Breanna C Isley1, Jeffery Boateng2, Jacob A Beierle3, Aaron Hansbury2, Hira Shrestha1, Camron Bryant3, Huiping Zhang4. 1. Department of Pediatrics, Boston Medical Center, Boston, MA 02119, USA. 2. Boston University School of Public Health, Boston, MA 02118, USA. 3. Laboratory of Addiction Genetics, Department of Pharmacology and Experimental Therapeutics and Psychiatry, Boston University School of Medicine, Boston, MA 02118, USA. 4. Department of Psychiatry, Boston University School of Medicine, Boston, MA 02118, USA.
Abstract
AIMS: Epigenetic variation of DNA methylation of the mu-opioid receptor gene (OPRM1) has been identified in the blood and saliva of individuals with opioid use disorder (OUD) and infants with neonatal opioid withdrawal syndrome (NOWS). It is unknown whether epigenetic variation in OPRM1 exists within placental tissue in women with OUD and whether it is associated with NOWS outcomes. In this pilot study, the authors aimed to 1) examine the association between placental OPRM1 DNA methylation levels and NOWS outcomes, and 2) compare OPRM1 methylation levels in opioid-exposed versus non-exposed control placentas. METHODS: Placental tissue was collected from eligible opioid (n = 64) and control (n = 29) women after delivery. Placental DNA was isolated and methylation levels at six cytosine-phosphate-guanine (CpG) sites within the OPRM1 promoter were quantified. Methylation levels were evaluated for associations with infant NOWS outcome measures: need for pharmacologic treatment, length of hospital stay (LOS), morphine treatment days, and treatment with two medications. Regression models were created and adjusted for clinical co-variates. Methylation levels between opioid and controls placentas were also compared. RESULTS: The primary opioid exposures were methadone and buprenorphine. Forty-nine (76.6%) of the opioid-exposed infants required pharmacologic treatment, 10 (15.6%) two medications, and average LOS for all opioid-exposed infants was 16.5 (standard deviation 9.7) days. There were no significant associations between OPRM1 DNA methylation levels in the six CpG sites and any NOWS outcome measures. No significant differences were found in methylation levels between the opioid and control samples. CONCLUSIONS: No significant associations were found between OPRM1 placental DNA methylation levels and NOWS severity in this pilot cohort. In addition, no significant differences were seen in OPRM1 methylation in opioid versus control placentas. Future association studies examining methylation levels on a genome-wide level are warranted.
AIMS: Epigenetic variation of DNA methylation of the mu-opioid receptor gene (OPRM1) has been identified in the blood and saliva of individuals with opioid use disorder (OUD) and infants with neonatal opioid withdrawal syndrome (NOWS). It is unknown whether epigenetic variation in OPRM1 exists within placental tissue in women with OUD and whether it is associated with NOWS outcomes. In this pilot study, the authors aimed to 1) examine the association between placental OPRM1 DNA methylation levels and NOWS outcomes, and 2) compare OPRM1 methylation levels in opioid-exposed versus non-exposed control placentas. METHODS: Placental tissue was collected from eligible opioid (n = 64) and control (n = 29) women after delivery. Placental DNA was isolated and methylation levels at six cytosine-phosphate-guanine (CpG) sites within the OPRM1 promoter were quantified. Methylation levels were evaluated for associations with infant NOWS outcome measures: need for pharmacologic treatment, length of hospital stay (LOS), morphine treatment days, and treatment with two medications. Regression models were created and adjusted for clinical co-variates. Methylation levels between opioid and controls placentas were also compared. RESULTS: The primary opioid exposures were methadone and buprenorphine. Forty-nine (76.6%) of the opioid-exposed infants required pharmacologic treatment, 10 (15.6%) two medications, and average LOS for all opioid-exposed infants was 16.5 (standard deviation 9.7) days. There were no significant associations between OPRM1 DNA methylation levels in the six CpG sites and any NOWS outcome measures. No significant differences were found in methylation levels between the opioid and control samples. CONCLUSIONS: No significant associations were found between OPRM1 placental DNA methylation levels and NOWS severity in this pilot cohort. In addition, no significant differences were seen in OPRM1 methylation in opioid versus control placentas. Future association studies examining methylation levels on a genome-wide level are warranted.
Authors: Andres Cardenas; Sharon M Lutz; Todd M Everson; Patrice Perron; Luigi Bouchard; Marie-France Hivert Journal: Am J Epidemiol Date: 2019-11-01 Impact factor: 4.897
Authors: Hendrée E Jones; Sarah H Heil; Michelle Tuten; Margaret S Chisolm; Julianne M Foster; Kevin E O'Grady; Karol Kaltenbach Journal: Drug Alcohol Depend Date: 2012-12-29 Impact factor: 4.492
Authors: Hendrée E Jones; Karol Kaltenbach; Sarah H Heil; Susan M Stine; Mara G Coyle; Amelia M Arria; Kevin E O'Grady; Peter Selby; Peter R Martin; Gabriele Fischer Journal: N Engl J Med Date: 2010-12-09 Impact factor: 91.245
Authors: Veeral N Tolia; Stephen W Patrick; Monica M Bennett; Karna Murthy; John Sousa; P Brian Smith; Reese H Clark; Alan R Spitzer Journal: N Engl J Med Date: 2015-04-26 Impact factor: 91.245
Authors: David A Nielsen; Vadim Yuferov; Sara Hamon; Colin Jackson; Ann Ho; Jurg Ott; Mary Jeanne Kreek Journal: Neuropsychopharmacology Date: 2008-07-23 Impact factor: 7.853
Authors: Elisabeth Conradt; Barry M Lester; Allison A Appleton; David A Armstrong; Carmen J Marsit Journal: Epigenetics Date: 2013-10-17 Impact factor: 4.528
Authors: Elisha M Wachman; A Hutcheson Warden; Zoe Thomas; Jo Ann Thomas-Lewis; Hira Shrestha; F N U Nikita; Daniel Shaw; Kelley Saia; Davida M Schiff Journal: Drug Alcohol Depend Date: 2018-09-01 Impact factor: 4.492
Authors: Elisabeth Conradt; Mary Fei; Linda LaGasse; Edward Tronick; Dylan Guerin; Daniel Gorman; Carmen J Marsit; Barry M Lester Journal: Front Behav Neurosci Date: 2015-05-29 Impact factor: 3.558
Authors: Kristyn N Borrelli; Elisha M Wachman; Jacob A Beierle; Elizabeth S Taglauer; Mayuri Jain; Camron D Bryant; Huiping Zhang Journal: Biomedicines Date: 2022-05-17